Watanabe Chizuko, Orito Tohru, Watanabe Hiroyuki, Mizoguchi Hirokazu, Yonezawa Akihiko, Yanai Kazuhiko, Mobarakeh Jalal Izadi, Onodera Kenji, Sakurada Tsukasa, Sakurada Shinobu
Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
Eur J Pharmacol. 2008 Feb 26;581(1-2):54-63. doi: 10.1016/j.ejphar.2007.11.027. Epub 2007 Nov 23.
Previous research has demonstrated that a high dose of histamine (1600 pmol) injected i.t. in mice can evoke nociceptive behaviors consisting of biting/licking along with occasional scratching. The present study was undertaken to examine the involvement of spinal N-methyl-d-aspartate (NMDA) and histamine H(1) and H(2) receptors in the nociceptive behaviors evoked by high-dose histamine. Co-administration of the histamine H(1) receptor antagonists, d-chlorpheniramine and pyrilamine, or the histamine H(2) receptor antagonists, ranitidine and zolantidine, failed to suppress the histamine-evoked nociceptive behaviors. Moreover, following histamine administration, nociceptive behaviors in histamine H(1) receptor-knockout and histamine H(2) receptor-knockout mice were indistinguishable from those in wild-type mice, suggesting that histamine-induced nociceptive behaviors are not mediated through histamine H(1) and H(2) receptors in the spinal cord. The histamine-induced nociceptive behaviors were inhibited by co-administration of the competitive NMDA receptor antagonists, d-(-)-2-amino-5-phosphonovaleric acid (D-APV) and 3-((+)-2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPPA), and the ion channel blocker, (5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5,10-imine maleate (MK-801). Co-administration of ifenprodil, an antagonist for both the polyamine site and the NR2B subunit of NMDA receptors, also inhibited the histamine-induced nociceptive behaviors. (R-[R, S])-alpha-(4-hydroxyphenyl)-beta-methyl-4-(phenylmethyl)-1-piperidinepropanol hydrochloride (Ro25-6981), an antagonist of the NMDA receptor subtype containing the NR2B subunit, did not inhibit histamine-induced nociceptive behaviors, whereas these behaviors were attenuated by pretreatment with an antisense oligodeoxynucleotide against the mRNA for the NR1 subunit of the NMDA receptor. Moreover, agmatine and arcaine, antagonists for a polyamine site on the NMDA receptor, inhibited nociceptive behaviors induced by histamine. These results suggest that a polyamine site on spinal NMDA receptors is involved in eliciting the nociceptive behavioral episode following intrathecal injection of histamine.
先前的研究表明,向小鼠鞘内注射高剂量组胺(1600皮摩尔)可引发伤害性反应行为,包括啃咬/舔舐以及偶尔的抓挠。本研究旨在探讨脊髓N-甲基-D-天冬氨酸(NMDA)受体以及组胺H(1)和H(2)受体在高剂量组胺引发的伤害性反应行为中的作用。组胺H(1)受体拮抗剂氯苯那敏和吡苄明,或组胺H(2)受体拮抗剂雷尼替丁和佐兰替丁的联合给药未能抑制组胺引发的伤害性反应行为。此外,给予组胺后,组胺H(1)受体基因敲除小鼠和组胺H(2)受体基因敲除小鼠的伤害性反应行为与野生型小鼠无异,这表明组胺诱导的伤害性反应行为并非通过脊髓中的组胺H(1)和H(2)受体介导。组胺诱导的伤害性反应行为可被竞争性NMDA受体拮抗剂D-(-)-2-氨基-5-磷酸戊酸(D-APV)和3-((+)-2-羧基哌嗪-4-基)-丙基-1-膦酸(CPPA)以及离子通道阻滞剂(5R,10S)-(+)-5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺马来酸盐(MK-801)的联合给药所抑制。NMDA受体多胺位点和NR2B亚基的拮抗剂艾芬地尔的联合给药也抑制了组胺诱导的伤害性反应行为。(R-[R,S])-α-(4-羟基苯基)-β-甲基-4-(苯基甲基)-1-哌啶丙醇盐酸盐(Ro25-6981),一种含有NR2B亚基的NMDA受体亚型的拮抗剂,并未抑制组胺诱导的伤害性反应行为,而这些行为可通过用针对NMDA受体NR1亚基mRNA的反义寡脱氧核苷酸预处理而减弱。此外,NMDA受体多胺位点的拮抗剂胍丁胺和肌氨酸抑制了组胺诱导的伤害性反应行为。这些结果表明,脊髓NMDA受体上的一个多胺位点参与了鞘内注射组胺后引发的伤害性反应行为过程。